Key Highlights
- Shares are trading up 8.79% at $233.29 versus a prior close of $214.44.
- Third-quarter Revenue hit a record $1.24 billion, up 10% year over year.
- 2026 revenue guidance was raised to $4.775 billion to $4.85 billion.
Jazz Pharmaceuticals (NASDAQ:JAZZ) shares are trading up 8.79% at $233.29 today after a third-quarter report that beat on revenue and raised full-year guidance for the second straight quarter. The stock sits within a 52-week range of $128.80 to $266.38 and is well above the $214.44 it closed at in the prior session.
Jazz Pharmaceuticals is a Dublin-headquartered global biopharmaceutical company founded in 2003 that develops and commercializes medicines for rare and serious diseases in neuroscience and oncology. Its marketed portfolio includes Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for rare epilepsies, and oncology products such as Zepzelca, Ziihera, Rylaze, Modeyso, Defitelio and Vyxeos. It has about 2,900 employees.
Record Revenue Led by Oncology and Xywav
Revenue reached a record $1.24 billion, up 10% year over year, led by 35% growth in oncology and 12% growth in Xywav to $483 million. Epidiolex net sales were $295 million, Ziihera contributed $21 million in its first launch quarter, Modeyso reached about $200 million cumulative since launch, and Zepzelca delivered $104 million, up 32%.
The headline non-GAAP loss of $3.88 per share reflected a $754 million Actio acquired in-process R&D charge. Excluding it, non-GAAP EPS would have been $7.15 with a tax rate near 13%. The company generated $1.3 billion in Operating Cash Flow over nine months, issued $1.25 billion in convertible notes and ended the quarter with $2.9 billion in cash and investments.
Guidance Raised With Early Ziihera Launch Metrics Encouraging
Full-year 2026 revenue guidance was raised and narrowed to $4.775 billion to $4.85 billion, about 13% growth at the midpoint. Rare sleep revenue is now expected at $2.125 billion to $2.175 billion, and non-GAAP gross Margin guidance rose to 90.5% to 91.5%.
Ziihera's first-line HER2-positive gastroesophageal adenocarcinoma launch is off to a strong start, with a threefold increase in new ordering accounts in September, about 80% from community settings and about 40% month-over-month growth in vial Demand per selling day. The target population is 3,000 to 4,000 U.S. patients, with peak sales potential of $3 billion to $5 billion.
Analyst Targets Move Higher and Key Milestones Lie Ahead
Morgan Stanley lifted its target to $319, JPMorgan to $310 and RBC to $305, while Barclays set $275. Management flagged that orexin agonists may delay NT1 Xywav starts, a competitor launch in 2027 is expected to touch Zepzelca, and Modeyso is expected to see a more measured near-term pace before ACTION data in the first half of 2027. The Epidiolex capsule PDUFA date is April 16, 2027.
Ziihera Ramp and 2027 Data Readouts Drive the Next Leg
With the stock still below its 52-week high of $266.38, the Ziihera ramp, initial ABS-1230 patient data this quarter and EMPOWER-BC 303 data in late 2027 or early 2028 are the milestones investors will follow.






Please wait processing your request...